Related Experiment Videos
Intercellular adhesion molecule 1 gene polymorphisms in Graves' disease.
Adam Kretowski1, Natalia Wawrusiewicz, Katarzyna Mironczuk
1Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, Poland. akretows@amb.ac.bialystok.pl
The Journal of Clinical Endocrinology and Metabolism
|October 15, 2003
Summary
Genetic variations in the intercellular adhesion molecule 1 (ICAM-1) gene are linked to Graves' disease (GD). Specific ICAM-1 polymorphisms are associated with earlier GD onset and an increased risk of Graves' ophthalmopathy.
Area of Science:
- Genetics
- Immunology
- Endocrinology
Background:
- Genetic factors are increasingly implicated in Graves' disease (GD) pathogenesis.
- Intercellular adhesion molecule 1 (ICAM-1) plays a crucial role in lymphocyte infiltration into the thyroid gland.
- Soluble ICAM-1 levels correlate with GD clinical activity and treatment status.
Purpose of the Study:
- To investigate the association between ICAM-1 gene polymorphisms (c.721G-->A and c.1405A-->G) and Graves' disease.
- To determine if these ICAM-1 polymorphisms correlate with the age of GD onset and the presence of Graves' ophthalmopathy.
Main Methods:
- Genotyping of ICAM-1 polymorphisms (c.721G-->A and c.1405A-->G) in 235 GD patients and 211 healthy controls.
- Statistical analysis to assess the association between polymorphisms, age of onset, and ophthalmopathy.
Main Results:
- The c.721G-->A polymorphism in the ICAM-1 gene was significantly associated with an earlier age of GD onset.
- The c.1405A-->G polymorphism of the ICAM-1 gene showed a potential predisposition to Graves' ophthalmopathy.
Conclusions:
- ICAM-1 gene polymorphisms, specifically G241R and K469E amino acid substitutions, may influence the autoimmune process in GD and orbital tissue infiltration.
- Targeting ICAM-1 function could be a potential therapeutic strategy for managing GD onset, remission, and clinical manifestations.